^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1)

    i
    Other names: PRKAG1, Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1, Protein Kinase, AMP-Activated, Gamma 1 Non-Catalytic Subunit, 5’-AMP-Activated Protein Kinase Subunit Gamma-1, AMPK Gamma1, 5’-AMP-Activated Protein Kinase, Gamma-1 Subunit, AMPK Subunit Gamma-1, AMPK Gamma-1 Chain, PRKAG1, AMPKG
    1m
    The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma. (PubMed, Precis Clin Med)
    RRSM is a potential prognostic predictor for STS and lays a foundation for early intervention of high-risk STS patients. The expression of genes FZD7, ITPKA, and PRKAG1 may guide STS treatment decisions.
    Journal
    |
    COL6A3 (Collagen Type VI Alpha 3 Chain) • PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1) • FZD7 (Frizzled Class Receptor 7) • ITPKA (Inositol-Trisphosphate 3-Kinase A)
    5ms
    Molecular mechanism of LncRNA MALAT1 in regulating hepatocellular carcinoma progression via the miR-383-5p/PRKAG1 axis and its role in the tumor immune microenvironment. (PubMed, Front Oncol)
    This study elucidates the oncogenic role of the MALAT1/miR-383-5p/PRKAG1 axis in HCC, demonstrating that PRKAG1 promotes tumor progression by regulating cell proliferation, the immune microenvironment, and key signaling pathways. These findings provide potential novel targets for HCC prognosis assessment and targeted therapy.
    Journal
    |
    CD4 (CD4 Molecule) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • MIR383 (MicroRNA 383)
    10ms
    A Novel Prognostic Signature Integrating Immune and Glycolytic Pathways for Enhanced Prognosis and Immunotherapy Prediction in Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    In vitro experiments indicated that PRKAG1 and B3GAT3 were upregulated, enhancing glycolysis and promoting HCC cell proliferation and migration. The IGRPS, based on immune- and glycolysis-related genes, effectively predicted prognosis and immunotherapy responses in HCC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1)
    almost4years
    N6-METHYLADENINE DNA DEMETHYLASE ALKBH1 PROMOTES GASTRIC CARCINOGENESIS VIA DISRUPTING NRF1 BINDING CAPACITY (DDW 2022)
    This led to a metabolic shift towards “Warburg” effect with an elevated extracellular acidification rate (ECAR) to oxygen consumption rate (OCR) ratio, thereby promoting a gastric tumorigenic phenotype. Conclusion : ALKBH1-driven DNA 6mA demethylation in GC plays an oncogenic role in GC by repressing NRF1-mediated transcription of AMPK targets, which promotes a “Warburg” phenotype and tumorigenesis.
    Epigenetic controller
    |
    NRF1 (Nuclear Respiratory Factor 1) • PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1)